On August 8, 2016 Storm Therapeutics, a spin-out company based upon the ground-breaking work of its founders, CRUK-funded Professor Tony Kouzarides and Professor Eric Miska, reported that it has secured £12 million in series ‘A’ funding (Press release, Cancer Research Technology, AUG 8, 2016, View Source [SID1234523500]). Cancer Research Technology has also granted Storm Therapeutics rights to license specific IP arising out of further research from Professors Kouzarides and Miska’s labs at the Gurdon Institute, University of Cambridge.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The series ‘A’ funding, from investors Imperial Innovations, Cambridge Innovation Capital, Merck Ventures and Pfizer Venture Investments, will be used to identify small molecule modulators of novel targets in RNA modification pathways and develop them into new classes of anti-cancer treatments.

Professors Tony Kouzarides and Eric Miska, co-founders of Storm Therapeutics, commented: "The work that our research groups are undertaking on non-coding RNA and the enzymes that modify this RNA is giving us incredibly interesting insights into how gene expression can be modified at a cellular level. The funding and support that Storm Therapeutics has received from its investors will allow the development of these insights into a new class of therapeutics ready to be taken into clinical trials."